

1. Duff LA, Kitson AL, Seers K, Humphris D. Clinical guidelines: an introduction to their development and implementation. *J Adv Nurs* 1996, 23:887–895.
2. Kalafati M, Bellali TH, Hatzopoulou M, Fytrou H, Koreli A, Hliopoulou A, Development of clinical guidelines. *Nosileftiki* 2007, 46(1):31–37.
3. <http://www.agreetrust.org/resource-centre/the-original-agree-instrument/the-original-agree-instrument-translations/>
4. ADAPTE Collaboration, Manual for Guideline Adaptation, 2007.
Ανακτήθηκε από:
<http://www.adapte.org/www/upload/actualite/pdf/Manual%20&%20Toolkit.pdf>
5. Shea B, Grimshaw J, Wells G, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol* 2007;7:10.
6. Cox RA, García-Palmieri MR. Cholesterol, Triglycerides, and Associated Lipoproteins. In: Walker HK, Hall WD, Hurst JW, editors. *Clinical Methods: The History, Physical, and Laboratory Examinations*. 3rd edition. Boston: Butterworths; 1990. Chapter 31. Available from:
<http://www.ncbi.nlm.nih.gov/books/NBK351/>
7. Thompson GR. The proving of the lipid hypothesis. *Current Opin Lipidol* 1999; 10:201–5.
8. Reckless J.P.D., Lawrence J.M. Hyperlipidemia (Hyperlipidaemia). *Encyclopedia of Food Sciences and Nutrition (Second Edition)*, Oxford; 2003; 3183–3192
9. Boon NA, Davidson SS. *Davidson's Principles and Practice of Medicine*, 20th Edition, Edinburgh; Toronto: Churchill Livingstone Elsevier; 2006.
10. Kreisberg RA, Oberman A: Medical management of hyperlipidemia/dyslipidemia. *J Clin Endocrinol Metab* 2003; 88(6):2445-61.
11. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial Hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol*. 2011; 5(3 suppl):S9–S17.
12. Lin Y, Mousa SS, Elshourbagy N, Mousa SA. Current status and future directions in lipid management: emphasizing low-density lipoproteins, highdensity lipoproteins, and triglycerides as targets for therapy. *Vasc Health Risk Manag*. 2010; 6:73-85.
13. Veerkamp MJ, de Graaf J, Hendriks JC, Demacker PN, Stalenhoef AF. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow up study. *Circulation* 2004; 109: 2980-5.

14. Tsimihodimos V. and Elisaf M. Editorial: Secondary Dyslipidemias. *Open Cardiovasc Med J.* 2011; 5: 22–23
15. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. *JAMA* 2009; 302; 1993–2000. [BT IV]
16. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. *Circulation* 2008; 118:2047–2056. [BT IV]
17. Taskinen MR, Barter PJ, Ehnholm C, Sullivan DR, Mann K, Simes J, Best JD, Hamwood S, Keech AC on behalf of the FIELD Study Investigators. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. *Diabetologia* 2010; 53: 1846–1855. [BT IV]
18. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. Meta-analysis of LDL-C, non-HDL-C and apo B as markers of cardiovascular risk. *Circulation*. 2011 May;4(3):337-45. [BT II]
19. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004;364:937-952. [BT IV]
20. Kastelein JJ, van der Steeg WA, Holme I, et al; TNT Study Group; IDEAL Study Group. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. *Circulation*. 2008;117:3002-3009. [BT III-1]
21. McCrindle B, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, Hayman LL, Daniels SR; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Nursing. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. *Circulation*. 2007;115:1948-1967. [BT IV]
22. Ridker PM, Kastelein JJ, Genest J, Koenig W. C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care. *Eur Heart J.* 2013 May;34(17):1258-61. [BT IV]
23. Conroy R, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG,

- Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham I. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003;24:987–1003. [BT II]
24. Berra K. Does nurse case management improve implementation of guidelines for cardiovascular disease risk reduction? *J Cardiovasc Nurs.* 2011 Mar-Apr;26(2):145-67 [BT IV]
 25. Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries.. *Cochrane Database Syst Rev.*2013 Feb 28. [BT I]
 26. AllenJK, Himmelfarb CR, Szanton SL, Bone L, Hill MN, Levine DM. COACH trial:a randomized controlled trial of nurse practitioner/community health worker cardiovascular diseaserisk reduction in urban community health centers: rationale and design*Contemp Clin Trials.* 2011 May;32(3):403-11. [BT III-1]
 27. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. *Eur J Clin Nutr* 2009;63:S5–S21. [BT IV]
 28. Huang J, Frohlich J, Ignaszewski AP. Systematic Review/Meta-analysis: The Impact of Dietary Changes and Dietary Supplements on Lipid Profile, *Canadian Journal of Cardiology* 27 (2011) 488–505. [BT I]
 29. Sirtori CR, Galli C, Anderson JW, Arnoldi A. Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins. *Atherosclerosis* 2009; 203:8–17. [BT IV]
 30. Sofi F, Abbate R, Gensini GF, Casini A. Evidences on the relationship between Mediterranean diet and health status. *Recenti Prog Med* 2009;100:127-31. [BT IV]
 31. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med.* 2013 Apr 4;368(14):1279-90. [BT IV]
 32. Michelle A. Micallef Manohar L. Garg. Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fattyacids and plant sterols in hyperlipidemic individuals. *Atherosclerosis* 204 (2009) 476–482. [BT II]
 33. Robbins CL, Dietz PM, Bombard J, Tregear M, Schmidt SM, Tregear SJ. Lifestyle interventions for hypertension and dyslipidemia among women of reproductive age. *Prev Chronic Dis* 2011;8(6):A123. [BT IV]

34. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. *Lancet* 2010;376:1670–1681. [BT I]
35. Baigent C, Landray MJ, Reith C, et al; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. *Lancet*. 2011;377:2181-2192. [BT II]
36. Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). *Clin Chem* 2009;55:473–480. [BT II]
37. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen A J, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. *BMJ* 2009;338:b2376. [BT I]
38. Wanyin Hou, Jicheng Lv, Vlado Perkovic, Lihong Yang, Na Zhao, Meg J. Jardine, Alan Cass, Hong Zhang, Haiyan Wang. Effect of Statin Therapy on Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease A Systematic Review and Meta-Analysis. *Eur Heart J*. 2013;34(24):1807-1817. [BT I]
39. Ridker et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. *Lancet* 2012;380(9841):565-571. [BT II]
40. Peter S. Sever, Choon L. Chang, Ajay K. Gupta, Andrew Whitehouse, Neil R. Poulter, on behalf of the ASCOT Investigators The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. *Eur Heart J* (2011) 32, 2525–2532. [BT II]
41. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2013 Jan 31;1. Review. [BT I]
42. Kostis JB, Breazna A, Deedwania PC, LaRosa JC; Treating to New Targets Steering Committee and Investigators. The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. *J Clin Hypertens (Greenwich)*. 2008 May;10(5):367-76. [BT II]
43. McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P; IN-PRACTICE study. Int J Clin Pract. 2010 Jul;64(8):1052-61 Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and

rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. [BT II]

44. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, DiAngelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet* 2010;375: 1634–1639. [BT III-2]
45. Zhou YH, Ye XF, Yu FF, Zhang X, Qin YY, Lu J, He J. Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention. *BMC Neurol.* 2013 Jan 3;13:1. [BT I]
46. Farnier M, Ducobu J, Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. *Am J Cardiol.* 2010 Sep 15;106(6):787-92. [BT II]
47. Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. *Am J Cardiol.* 2010 May 15;105(10):1409-12. [BT II]
48. Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). *Am J Cardiol.* 2012 Oct 1;110(7):984-92. [BT IV]
49. Levy P. Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus. *Metab Syndr Relat Disord* 2010;8(suppl 1):S9–S13. [BT IV]
50. Ballantyne CM, Miller M, Niesor EJ, Burgess T, Kallend D, Stein EA. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. *Am Heart J.* 2012 Mar;163(3):515-21. [BT II]
51. Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, Jukema JW, Flaim JD, Su J, Yu R, Baker BF, Wedel MK, Kastelein JJ. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. *J Am Coll Cardiol.* 2010 Apr 13;55(15):1611-8. [BT II]
52. Naci H, Bruggs J, Andes AE. Comparative tolerability and harms of individual statins: A study-level network meta-analysis of 246 955

- participants from 135 randomized controlled trial. *Circ Cardiovasc Qual Outcomes* 2013. [BT I]
53. Rasmussen JN, Chong A, Alten DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. *JAMA* 2007;297:177–186 [BT IV]
 54. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. *JAMA* 2002;288(4):455–61. [BT III-2]
 55. Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, Holden A, De Bacquer D, Collier T, De Backer G, Faergeman O; EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. *Lancet* 2008;371:1999–2012. [BT II]
 56. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. *Pharmacotherapy* 2005;25(8):1035–43. [BT I]
 57. Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: a lost opportunity. *Pharmacotherapy* 2001;21(5):576–82. [BT IV]
 58. Reiner Z, Sonicki Z, Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors: the PERCRO survey. *Prev Med* 2010;51:494–496. [BT IV]
 59. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. *Cochrane Database Syst Rev.* 2010 Mar 17;(3). [BT I]
 60. Eaton CB, Parker DR, Borkan J, et al. Translating cholesterol guidelines into primary care practice: a multimodal cluster randomized trial. *Ann Fam Med.* 2011;9(6):528-537 [BT III-1]
 61. Heneghan CJ, Glasziou PP, Perera R. Reminder packaging for improving adherence to self-administered long-term medications. *Cochrane Database of Systematic Reviews* 2006, Issue 1. [BT II]
 62. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. *Cochrane Database of Systematic Reviews* 2008, Issue 2. [BT IV]
 63. Akbari A, Mayhew A, Al-Alawi MA, Grimshaw J, Winkens R, Glidewell E, Pritchard C, Thomas R, Fraser C. Interventions to improve outpatient referrals from primary care to secondary care. *Cochrane Database Syst Rev;* 2008. [BT I]

64. Αδαμακίδου, Θ., Καλοκαιρινού-Αναγνωστοπούλου, Α. Το οργανωτικό πλαίσιο της Πρωτοβάθμιας Φροντίδας Υγείας στην Ελλάδα. ΝΟΣΗΛΕΥΤΙΚΗ; 2008, 47(3):320–333. [BT IV]
65. Isaacs AJ, Critchley JA, Tai SS, et al. Exercise Evaluation Randomized Trial (EXERT): a randomised trial comparing GP referral for leisure centre-based exercise, community-based walking and advice only. Health Technol Assess; 2007;11:1-165. [BT I]
66. National Institute for Health and Clinical Excellence. Four commonly used methods to increase physical activity: brief interventions in primary care, exercise referral schemes, pedometers and community based exercise programmes for walking and cycling. London: NICE; 2006. [BT IV]
67. Brief interventions and referral for smoking cessation in primary care and other settings. NICE Public health intervention guidance 1; 2006. Available from <http://guidance.nice.org.uk/PH1> [BT IV]
68. Rees K, Dyakova M, Ward K, Thorogood M, Brunner E. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev. 2013 Mar 28;3 [BT I]
69. Lionis C, Symvoulakis EK, Markaki A, Vardavas C, Papadakaki M, Daniilidou N, Souliotis K, Kyriopoulos I. Integrated primary health care in Greece, a missing issue in the current health policy agenda: a systematic review. Int J Integr Care. 2009 Jul 30;9. [BT IV]
70. Kontodimopoulos N, Moschovakis G, Aletras VH, Niakas D. The effect of environmental factors on technical and scale efficiency of primary health care providers in Greece. Cost Effectiveness and Resource Allocation 2007;5:14. [BT IV]
71. Θεοδώρου Μ, Σίσκου Ο, Καϊτελίδου Δ, Φαρατσέλη Ο, Λιαρόπουλος Λ. Η οργάνωση και διοίκηση των υπηρεσιών ΠΦΥ στην Ελλάδα. Στο: Υπουργείο Υγείας και Κοινωνικής Αλληλεγγύης, Τρίτο Περιφερειακό Σύστημα Υγείας Πρόνοιας Αττικής (Επιμ.) Θεωρία και Πρακτική της Πρωτοβάθμιας Φροντίδας Υγείας. Πειραιάς, 2005:23–449 [BT IV]
72. Downs J, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615
73. Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:1155–1163.
74. Cholesterol Treatment Trialists Collaboration, Kearney PM, Blackwell L et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117–25.

